PMID- 22271188
OWN - NLM
STAT- MEDLINE
DCOM- 20121204
LR  - 20220409
IS  - 1759-5037 (Electronic)
IS  - 1759-5029 (Linking)
VI  - 8
IP  - 4
DP  - 2012 Jan 24
TI  - The emerging role of HDL in glucose metabolism.
PG  - 237-45
LID - 10.1038/nrendo.2011.235 [doi]
AB  - A low plasma level of HDL cholesterol is an atherosclerotic risk factor; however, 
      emerging evidence suggests that low HDL levels might also contribute to the 
      pathophysiology of type 2 diabetes mellitus (T2DM) through direct effects on 
      plasma glucose. In the past decade, animal and clinical studies have uncovered a 
      previously undescribed spectrum of HDL actions, indicating that HDL may control 
      glucose homeostasis through mechanisms including insulin secretion, direct 
      glucose uptake by muscle via the AMP-activated protein kinase, and possibly 
      enhanced insulin sensitivity. These effects are mediated by multiple cell types 
      via mechanisms including preservation of cell function through cellular lipid 
      removal and also via direct signaling events. We suggest a paradigm shift from 
      HDL being a bystander to being an active player in diabetic pathophysiology, 
      which raises the possibility that HDL elevation could be a novel therapeutic 
      avenue for T2DM. The entry of HDL-raising agents of the cholesteryl ester 
      transfer protein (CETP) inhibitor class into late-phase clinical trials creates 
      potential for rapid clinical translation. This Review will discuss the emerging 
      evidence for a role of HDL-mediated glucose regulation in the pathophysiology of 
      T2DM, and will also outline the therapeutic potential for HDL elevation for the 
      prevention and management of T2DM.
FAU - Drew, Brian G
AU  - Drew BG
AD  - Metabolic and Vascular Physiology Laboratory, Baker IDI Heart & Diabetes 
      Institute, PO Box 6492, St Kilda Road Central, Melbourne, VIC 8008, Australia.
FAU - Rye, Kerry-Anne
AU  - Rye KA
FAU - Duffy, Stephen J
AU  - Duffy SJ
FAU - Barter, Philip
AU  - Barter P
FAU - Kingwell, Bronwyn A
AU  - Kingwell BA
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120124
PL  - England
TA  - Nat Rev Endocrinol
JT  - Nature reviews. Endocrinology
JID - 101500078
RN  - 0 (Blood Glucose)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Insulin)
RN  - 0 (Lipoproteins, HDL)
SB  - IM
MH  - Animals
MH  - Blood Glucose/*metabolism
MH  - Cholesterol, HDL/blood/*physiology
MH  - Diabetes Mellitus, Type 2/*blood/diagnosis/therapy
MH  - Humans
MH  - Insulin/blood
MH  - Lipoproteins, HDL/blood/physiology
EDAT- 2012/01/25 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/01/25 06:00
PHST- 2012/01/25 06:00 [entrez]
PHST- 2012/01/25 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - nrendo.2011.235 [pii]
AID - 10.1038/nrendo.2011.235 [doi]
PST - epublish
SO  - Nat Rev Endocrinol. 2012 Jan 24;8(4):237-45. doi: 10.1038/nrendo.2011.235.